1. Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity
- Author
-
Christian Cadeddu Dessalvi, Martino Deidda, Clelia Madeddu, Maurizio Galderisi, Ciro Santoro, Teresa López-Fernández, Lucia Cugusi, Antonio Noto, Giuseppe Mercuro, Cadeddu Dessalvi, Christian, Deidda, Martino, Noto, Antonio, Madeddu, Clelia, Cugusi, Lucia, Santoro, Ciro, López-Fernández, Teresa, Galderisi, Maurizio, and Mercuro, Giuseppe
- Subjects
Antioxidant ,Cardiotonic Agents ,Heart Diseases ,Physiology ,medicine.medical_treatment ,Clinical Biochemistry ,Antineoplastic Agents ,Pharmacology ,medicine.disease_cause ,Biochemistry ,Redox ,Antioxidants ,Chemotherapy induced ,medicine ,Humans ,Molecular Biology ,Normal heart ,General Environmental Science ,chemistry.chemical_classification ,Cardioprotection ,Heart Failure ,Reactive oxygen species ,Cardiotoxicity ,chemotherapy-induced cardiotoxicity ,Cell Biology ,Oxidative Stress ,chemistry ,cardioprotection ,General Earth and Planetary Sciences ,Reactive Oxygen Species ,Oxidative stress - Abstract
Significance: Chemotherapy-induced cardiotoxicity (CTX) has been associated with redox signaling imbalance. In fact, redox reactions are crucial for normal heart physiology, whereas excessive oxidative stress can cause cardiomyocyte structural damage. Recent Advances: An antioxidant approach as a cardioprotective strategy in this setting has shown encouraging results in preventing anticancer drug-induced CTX. Critical Issues: In fact, traditional heart failure drugs as well as many other compounds and nonpharmacological strategies, with a partial effect in reducing oxidative stress, have been shown to counterbalance chemotherapy-induced CTX in this setting to some extent. Future Directions: Given the various pathways of toxicity involved in different chemotherapeutic schemes, interactions with redox balance need to be fine-tuned and a personalized cardioprotective approach seems to be required.
- Published
- 2020